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Abstract
We conducted a 6 month, randomized trial of parent training (PT) versus a parent education 
program (PEP) in 180 young children (158 boys, 22 girls), ages 3–7 years, with autism spectrum 
disorder (ASD). PT was superior to PEP in decreasing disruptive and noncompliant behaviors. In 
the current study, we assess moderators of treatment response in this trial. Thirteen clinical and 
demographic variables were evaluated as potential moderators of three outcome variables: the 
Aberrant Behavior Checklist-Irritability subscale (ABC-I), Home Situations Questionnaire (HSQ), 
and Clinical Global Impressions-Improvement Scale (CGI-I). We used an intent-to-treat model 
and random effects regression. Neither IQ nor ASD severity moderated outcome on the selected 
outcome measures. Severity of Attention Deficit Hyperactivity Disorder (ADHD) and anxiety 
moderated outcomes on the ABC-I and HSQ. For instance, there was a 6.6 point difference on the 
ABC-I between high and low ADHD groups (p = .05) and a 5.3 point difference between high and 
low Anxiety groups (p = .04). Oppositional defiant disorder symptoms and household income 
moderated outcomes on the HSQ. None of the baseline variables moderated outcome on the CGI-
I. That IQ and ASD symptom severity did not moderate outcome suggests that PT is likely to 
benefit a wide range of children with ASD and disruptive behavior.
Keywords
Autism spectrum disorder; parent training; moderator; ADHD; anxiety
Autism Spectrum Disorder (ASD) is a heterogeneous condition of early childhood onset 
defined by impaired social communication, repetitive behavior and restricted interests. 
Available evidence suggests that ASD affects approximately 6 per 1,000 children with about 
30% functioning in the range of intellectual disability (Elsabbagh, Divan, Koh, Kim, 
Kauchali, Marcin, Montiel-Nava, Patel, Paula, Wang, Yasamy & Fombonne, 2012). Many 
children with ASD also exhibit behavioral problems such as tantrums, aggression, self-
injury, hyperactivity, impulsiveness and noncompliance (Gadow, DeVincent, Pomeroy, 
Azizian, 2005; Kaat and Lecavalier, 2013). These co-occurring behavioral problems can 
pose enormous challenges to parents, lead to more restrictive school placements and the 
need for intensive behavioral interventions, medication or both.
Two medications, risperidone and aripiprazole, have demonstrated efficacy for the treatment 
of serious behavioral problems in children with ASD (Owen et al., 2009; Research Units on 
Pediatric Psychopharmacology [RUPP] Autism Network, 2002). Many parents and 
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clinicians, however, may be reluctant to use these potent drugs in young children. 
Interventions based on the principles of applied behavior analysis (ABA) also can help 
reduce behavior problems (Beavers et al., 2013; Wong et al., 2014). To date, most ABA 
studies in this population used individualized single-subject design studies. An emerging 
literature on the use of structured parent training (PT) in children with ASD and disruptive 
behavior offers encouraging results (McIntyre, 2008; Tonge, Brereton, Kiomall, Mackinnon 
& Rinehart, 2014). In children with disruptive behavior uncomplicated by ASD, PT is 
considered an evidenced-based intervention (Dretzke et al., 2009; Michelson, Daveport, 
Dretzke, Barlow & Day, 2013; Ollendick, Jarrett, Grills-Taquechel, Hovey & Wolf, 2008). 
The limited specialized resources amidst the growing number of children identified with 
ASD makes PT especially appealing.
In a prior publication, we showed that a structured PT intervention based on ABA principles 
was superior to a parent education program (PEP) in reducing disruptive and noncompliant 
behavior in young children with ASD (Bearss et al., 2015). This study of 180 children was 
the largest randomized controlled trial (RCT) to date of PT aimed at reducing behavior 
problems in ASD. Other strengths of the study included the 24-week duration, 24-week 
post-treatment follow-up, and use of PEP as an active comparator to control for therapist 
attention and maturation. After 24 weeks of treatment, PT was superior to PEP on the 
parent-rated Irritability subscale of the Aberrant Behavior Checklist (ABC; effect size = 
0.62; p < .001) and the total Score of the Home Situations Questionnaire (HSQ; effect size = 
0.45; p < .001). The positive response rates on the Clinical Global Impression-Improvement 
(CGI) scale completed by a masked rater were 68.5% for PT versus 39.6% for PEP (p < .
001).
In this report, we focus on moderators of treatment outcome from this multisite RCT. 
Moderating variables are baseline characteristics that significantly affect the pre-specified 
primary and key secondary outcomes. The identification of moderators may provide insight 
on subgroups that may be more or less likely to respond to an efficacious treatment. To 
minimize type 1 error, we selected a priori candidate demographic and clinical variables that 
could have a prognostic influence on outcome. In terms of demographic variables, we 
focused on the child’s IQ, socioeconomic status, and educational placement. We 
hypothesized that group differences favoring PT would be more pronounced in higher 
functioning children and those with less family adversity. In terms of clinical variables, we 
focused on the severity of co-occurring attention- deficit/hyperactivity disorder (ADHD), 
oppositional defiant disorder (ODD), and anxiety, as well as the severity of ASD symptoms 
and compulsive behaviors. We hypothesized that group differences favoring PT would be 
more pronounced in children with milder comorbidities (ADHD, ODD, and anxiety) and 
less severe ASD symptoms. Selected variables were based on clinical consensus and prior 
research on behavioral interventions in children with ASD, ADHD, or ODD/CD 
(Beauchaine, Webster-Stratton & Reid, 2005; Chronis, Chacko, Fabiana, Wymbs & Pelham., 
2004; Lundahl, Risser, Lovejoy, 2005; MTA Cooperative Group, 1999; Ollendick et al., 
2008; Rogers, 1998).
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Methods
Design
The background, methods, and main findings from the study have been reported elsewhere 
(Bearss et al., 2015). Briefly, the study was an RCT conducted at six sites (Emory 
University, Indiana University, Ohio State University, University of Pittsburgh, University of 
Rochester, Yale University). The trial was approved by the institutional review boards at 
each site. Informed consent was obtained from all individual participants included in the 
study. Eligible children were randomly assigned in 1:1 ratio to PT or PEP for 24 weeks 
using permuted blocks with concealed allocation to investigators. Parents and therapists 
were not blind to treatment. Assessments, completed every 4 weeks, included several parent 
ratings and interviews by an independent blinded clinician. At endpoint, the independent 
evaluator rated each child’s treatment response as positive or not on the CGI-I. A positive 
response on the CGI-I was defined as a score of 1 (Very Much Improved) or 2 (Much 
Improved). Subjects and families in the PT group were invited to return for assessment at 
weeks 36 and 48 to evaluate longer-term outcomes. Parents received compensation to cover 
travel costs for each assessment and therapy visit. The study results, adverse events, 
enrollment and attrition were reviewed by an external data and safety monitoring board 
every 6 months.
Participants
One-hundred-eighty children between the ages of 3 and 7 years inclusive participated in the 
24-week study targeting disruptive and noncompliant behaviors. Children were randomized 
to either the PT program or PEP. Inclusion criteria required an ASD diagnosis, a score > 15 
on the Irritability subscale of the ABC (described below) and a CGI Severity (CGI-S) score 
> 4. Participants could take medication, as long as it had been stable for 6 weeks and there 
were no planned changes for the course of the study. Exclusion criteria encompassed any 
serious medical conditions or psychiatric disorder, receptive language skills < 18 months, 
and current or past enrollment in structured PT. Clinical diagnosis of ASD was made 
according to DSM-IV-TR criteria (American Psychiatric Association, 2000), based on a 
comprehensive clinical assessment and corroborated by the Autism Diagnostic Interview-
Revised (ADI-R; Rutter, Le Couteur & Lord, 2003) and Autism Diagnostic Observation 
Schedule (ADOS; Lord et al., 2000) completed by clinicians trained to reliability.
Measures
Outcome measures—Aberrant Behavior Checklist (ABC; Aman, Singh, Stewart, & 
Field, 1985a; Aman, Singh, Steward & Field, 1985b) is a 58-item rating scale. Each item is 
rated on a Likert scale from 0 (not a problem) to 3 (severe in degree). The ABC contains five 
subscales: I) Irritability (15 items), II) Social Withdrawal (16 items), III) Stereotypic 
Behavior (7 items), V) Hyperactivity/Noncompliance (16 items), and V) Inappropriate 
Speech (4 items). The ABC is reliable, valid, and sensitive to treatment effects in ASD 
(Kaat, Aman, Lecavalier, 2014). It was completed at baseline and every 4 weeks thereafter.
Home Situations Questionnaire – Autism Spectrum Disorder (HSQ) is a 24-item parent 
rating scale that assesses noncompliance. Parents are asked to indicate whether or not each 
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item is a problem and, if so, to rate its severity on a Likert scale from 1 (mild) to 9 (severe). 
Originally developed as a measure of disruptive behavior in children with Attention Deficit 
Hyperactive Disorder (Barkley & Edelbrock, 1987), it was adapted by the RUPP Autism 
Network to evaluate noncompliance in children with ASD (Chowdhury et al., 2015). We 
report average per item score. It was completed at baseline and every 4 weeks thereafter.
Clinical Global Impressions - Improvement Scale (CGI; Guy 1976) is a 7-point scale 
designed to measure overall improvement from baseline. Scores range from 1 (very much 
improved) through 4 (unchanged) to 7 (very much worse). Scores of 1 or 2 identified clinical 
responders. A blinded evaluator completed the CGI-I every 4 weeks after baseline.
Moderator variables—Early Childhood Inventory (ECI; Sprafkin, Volpe, Gadow, Nolan 
& Kelly, 2002) is a DSM-IV-referenced, parent report of child behavior. Items are scored 
from 0 (never) to 3 (very often) and can be scored in two different ways: symptom count 
(number of items rated 2 or 3) and symptom severity (sum of the scores for the specific 
diagnostic subscale). The scale has been shown to be valid in young children with ASD 
(Lecavalier, Gadow, DeVincent, Houts & Edwards, 2011). Of interest in the current study 
were the following subscales: attention-deficit/hyperactivity disorder (ADHD; 18 items), 
oppositional defiant disorder (ODD; 8 items), pervasive developmental disorder (PDD; 12 
items), and 16-items measuring anxiety (Hallett et al., 2013). The ADHD subscale was used 
dimensionally (i.e., symptom severity) and categorically (i.e., symptom count in accordance 
with DSM-IV).
Autism Diagnostic Observation Schedule (ADOS; Lord et al., 2000) is an investigator-based 
assessment conducted in naturalistic social situations demanding specific social, 
communication and restricted/repetitive responses. Behaviors are scored in the areas of 
social communication, social relatedness, play and imagination, and repetitive behaviors. 
This measure was used to support the clinical diagnosis and provides a severity score.
Children’s Yale-Brown Obsessive-Compulsive Scales-PDD (CYBOCS-PDD; Scahill et al., 
2006). The CYBOCS-PDD is a modified version of the CYBOCS developed for use in 
children with Obsessive Compulsive Disorder (Scahill et al., 1997). The modified version is 
a semi-structured clinician-rated scale designed to rate the current severity of repetitive 
behavior in children with ASD (Scahill et al., 2006). Current repetitive behaviors are rated 
on 5 dimensions: Time Spent, Interference, Distress, Resistance, and Control. Each 
dimension is scored on a 5-point scale from 0 (least symptomatic) to 4 (most symptomatic), 
yielding a Total score from 0 to 20. The CYBOCS-PDD has established reliability and 
validity and is sensitive to change in ASD.
Developmental/Cognitive functioning: The Stanford-Binet Fifth Edition (SB-V; Roid, 
2003) or the Mullen’s Scale of Early Learning (MSEL; Mullen, 1995) were used according 
to the developmental level of the child. The SB-V was attempted with all children, and, 
whenever possible, the abbreviated version was completed. The Mullen was administered to 
the minority of children who did not achieve a basal score on the SB-V because of limited 
language skills or mental age below 2–3 years.
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Treatments
The PT consisted of 11 sessions delivered individually and included direct instruction, video 
vignettes, role playing, and homework to be completed between sessions. Sessions lasted 
75–90 minutes. Parents were educated on behavioral principles and on a host of behavioral 
intervention strategies such as use of visual cues and reinforcement, as well as the teaching 
of compliance and other adaptive skills (Bearss, Jonhson, Handen et al., 2015). The PEP 
consisted of 12 individually-delivered that covered useful topics for parents of young 
children with ASD, including etiology of ASD, educational planning, advocacy, and 
selecting effective treatments (see Bearss et al., 2015). PEP sessions were the same duration 
as PT sessions. PEP was chosen as an active comparison group to control for time and 
therapist attention, allowing us to determine if information alone would improve behavior 
problems.
Data Analysis
To minimize type 1 error, we selected variables a priori as candidates that could influence 
outcome. Demographic variables included ethnicity, socioeconomic status, maternal 
education and intact family constitution or not. Child variables included educational 
placement, estimated IQ (< 70 or ≥ 70) as well as severity indices of ASD, ADHD, ODD, 
anxiety and repetitive behavior.
Random effects regression, including random effects for intercept and slope and fixed effects 
for baseline outcome variable, treatment (PT or PEP), time (as a continuous variable), site, 
educational intensity, and the interaction between time and treatment, was used in the 
original trial analysis. In the current analysis, similar models were employed adding fixed 
effects for the putative moderator variables and the interactions of moderators, treatment and 
time. No significant two-way interactions of moderators by treatment were observed 
demonstrating that moderation of treatment differences required follow-up time to develop. 
This was evaluated using three-way interactions (moderator by treatment by time) which 
evaluate whether the treatment difference in the rate of change for an outcome was 
dependent on the moderator variable.
To illustrate the moderation effect, the least squares mean treatment difference and 95% 
confidence interval at the week 24 endpoint was generated for each level of moderator 
variable and was presented in a forest plot. Statistical significance of moderators measured 
on a continuous scale was evaluated using the continuous variable. For ease of presentation 
and interpretation, continuous moderators were split above and below the 75th percentile to 
demonstrate differences in magnitudes of treatment effects across the moderator.
All analyses were performed using SAS 9.4 (Cary, NC) and statistical significance evaluated 
at the two-sided 0.05 significance level.
Results
Table 1 summarizes baseline demographic and clinical characteristics. It was not possible to 
estimate IQ for 17 children who did not complete the SB-5 or the Mullen subtests. Of these, 
15 children did complete the Mullen Receptive Language subtest to confirm the > 18-month 
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receptive language entry criterion. Based on their Receptive Language T-scores, a panel of 
psychologists classified these subjects as IQ < 70 (n = 10 in PT; n = 5 in PEP) for analytic 
purposes. The remaining two children could not be tested; they were allowed to enter the 
study following individual case reviews by senior investigators and were not classified as 
above or below 70.
Figure 1 shows forest plots for potential moderators with the ABC-I as the outcome 
measure. The X-axis represents treatment differences in ABC-I (PT minus PEP) at week 24 
whereby negative scores indicated a better treatment response in PT than PEP (i.e. ABC-I 
scores were lower in PT at 24 weeks compared to PEP). For continuous moderators, the red 
circles represent children in the top quartile (above the 75th percentile), while the blue 
squares represent children in the lower three quartiles (at or below the 75th percentile). 
ADHD total score (p = 0.05), ABC hyperactivity score (p = 0.03), ECI-anxiety (p = 0.04) 
and ECI categorized probable ADHD (p = 0.01) significantly moderated the treatment 
response. The benefit of PT was significantly greater for those with lower ADHD scores, 
treatment difference = −5.54, 95% confidence interval (CI) [−8.06 – −3.02]; compared to 
those with higher scores, 1.13, 95% CI [−3.66–5.93]. Those with lower ABC hyperactivity 
had a greater PT benefit, −4.96; 95% CI [−7.46,– −2.46] compared to those with higher 
scores, −0.37, CI 95% [−5.15–4.41]. The difference between PT and PEP was also more 
pronounced in those with lower ECI-anxiety scores, −5.26, 95% CI[−7.8– −2.67] compared 
to those with higher scores, 0.005 (−4.45–4.46)]. Finally, when the ECI was used to classify 
children with or without probable ADHD, children with probable ADHD showed no 
difference between treatment groups, −0.65, 95% CI [−4.19–2.90] on ABC-I. Children 
without probable ADHD showed greater PT benefit −6.29, 95% CI [−9.10 – −3.47].
Figure 2 shows forest plots for potential moderators with the HSQ as the outcome measure. 
These plots are to be interpreted in the same way as Figure 1. Treatment differences were 
significantly modified by ECI-ODD (p =0.05), ECI-anxiety (p =0.01), ECI-categorized 
probable ADHD (p = 0.03), and household income (p = 0.01). The magnitude of the PT 
effect was greater in those with lower [−0.91 (−1.37, −0.45)] compared to higher ODD 
symptoms [−0.16 (−1.01, 0.70)]; lower [−0.92 (−1.38, −0.45)] compared to higher ECI-
anxiety scores [−0.05(−0.86, 0.75)]; those without [−1.02 (−1.54, −0.51)] compared to with 
ECI categorized probable ADHD [−0.25 (−0.90, 0.39)] and when household income was 
above [−0.88 (−1.35, −0.40)] compared to below $40,000 [−0.15 (−0.91, 0.61)]. Although 
these factors moderated the treatment effect of PT compared to PEP, there was evidence of 
improvement in PT and PEP in children with higher levels of oppositional behavior, ADHD 
symptom and anxiety. For example, treatment difference in ABC-I scores from baseline to 
week 24 were −10.3 and −11.9 for high-ECI ADHD groups in PT and PEP, respectively. 
Likewise, treatment difference in HSQ scores from baseline to week 24 were −2.4 and −2.1 
for high-ECI ODD groups in PT and PEP, respectively. Similarly, treatment difference in 
HSQ scores from baseline to week 24 were −2.3 and −2.7 for high-ECI anxiety groups in PT 
and PEP, respectively.
Figure 3 shows forest plots for moderator variables with the CGI-I as the outcome measure. 
The X-axis is the odds ratio of positive response (much improved or very much improved) of 
PT compared to PEP. Analyses from the original trial showed a significantly higher rate of 
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positive response in PT compared to the PEP group. However, none of the moderators 
evaluated here significantly modified the likelihood of positive response between PT and 
PEP on the CGI-I.
Discussion
These analyses showed that ADHD and anxiety symptom-severity moderated outcome on 
both the ABC-I and the HSQ. In children with lower parent-rated symptoms of ADHD and 
anxiety on the ECI, there was a significantly greater difference in PT on the ABC-I and HSQ 
compared to PEP. This finding was evident with both dimensional and categorical scores for 
ADHD on the ABC-I, where the difference between high and low ADHD groups was about 
6 points. As reported in Bearss et al., (2015) the treatment difference between PT and PEP 
was 4.6 points on the ABC-I. These results indicate that the significant difference between 
groups was driven by the change in the children with lower levels of hyperactivity. 
Nonetheless, children with higher ADHD scores showed improvement on the ABC-I and 
HSQ. The benefits were roughly equal for PT and PEP.
Hyperactivity, impulsiveness and distractibility are common co-occurring problems in 
children with ASD (Simonoff et al., 2008). Children with ASD plus ADHD show lower 
rates of positive response to ADHD medications compared to children ADHD without ASD 
(RUPP Autism Network, 2005; Scahill et al., 2015). These children may also have greater 
adaptive skill deficits relative to their cognitive abilities than children who have ASD 
without ADHD (Ashwood et al., 2015).
There is evidence for the efficacy of behavioral PT for ADHD in children without ASD 
(Lee, Niew, Yang, Chen & Lin, 2012; Ollendick et al., 2008). This seems to be particularly 
true in preschoolers (Webster-Stratton, Reid & Beauchaine, 2011; Jones, Daley, Hutchings, 
Bywater & Eames, 2007). However, some studies have reported no benefits of PT on 
symptoms of ADHD (e.g., Van Den Hoofdakker et al., 2003). The evidence is not as clear 
and consistent as the evidence for PT in ODD/CD without ADHD (Dretzke et al., 2009; 
Michelson et al., 2013; Webster-Stratton et al., 2011). Indeed, severe hyperactivity and 
impulsiveness seem to present a greater challenge for the application of behavior 
management techniques.
A trial of atomoxetine and PT in 128 children (mean age 8 years) with ASD and ADHD is 
relevant to the current findings (Handen et al., 2015). In this study, children were 
randomized to one of four conditions: drug only, drug and PT, placebo, or PT with pill 
placebo. This 10-week study used a briefer, but similar PT program. On the HSQ, the PT 
group showed less improvement than the atomoxetine group, and was not significantly 
different from the placebo group. The results of this study also suggest that ADHD 
symptoms presents additional treatment challenges in children with ASD.
The presence of higher parent ratings of anxiety also predicted a smaller treatment effect for 
PT compared to PEP on both the ABC-I and the HSQ. Others have suggested that low-
anxiety children with disruptive behavior problems may be optimally responsive to 
interventions that focus on altering instrumental operant contingencies within the home 
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(Beauchaine et al., 2005). Along these lines, Pincus, Santucci, Ehrenreich and Eyeberg, 
(2008) found that Parent-Child Interaction Therapy without modifications was not effective 
as a stand-alone treatment to reduce childhood anxiety (n = 10; average age = 6 years). 
Although the current PT was not designed to target anxiety symptoms, it may be that more 
severe anxiety symptoms interfere with the treatment of disruptive and noncompliant 
behaviors. Similarly, disruptive and noncompliant behaviors could stem from anxiety rather 
than ASD (Bearss et al., 2016). This has been documented in children without ASD, where 
improvement in anxiety mediated improvement in disruptive behaviors (Arnold et al., 2015).
On balance, however, these results do not imply that children with ADHD or anxiety 
symptoms will not benefit from PT. For example, the likelihood of positive response on the 
CGI-I were not different across high- and low- ADHD or anxiety groups. Moreover, 
potentially relevant moderators such as IQ and ASD severity were not significant, suggesting 
that PT will benefit children with a range of impairments. Our examination of 
socioeconomic metric such as parent education, two-parent family, and household income 
was limited by the lack of variability in our sample. Nevertheless, only one of the nine 
analyses was significant (household income moderated outcome on the HSQ). In contrast, a 
number of socioeconomic status variables such as single parent status, young parent age, 
unstable housing, and reliance on government subsidies have been associated with poorer PT 
outcome in children without ASD (Lundahl et al., 2005). Socioeconomic adversity could 
undermine the efficacy of PT by disrupting the implementation of the intervention. Further 
study is needed to explore the application of PT in lower socioeconomic groups and rural 
samples.
Our results should be interpreted with a few caveats. Although this study is the largest to 
date of a behavioral intervention in children with ASD, the sample is rather small given the 
number of comparisons. The study of moderators was not the primary objective of the trial 
and therefore was exploratory in nature and requires replication. In addition, the significant 
associations were based on parent ratings who were not blinded to treatment assignment.
The results of the current study may inform the sequencing of treatment for children with 
ASD and disruptive behavior problems. Children with prominent symptoms of ADHD or 
anxiety may need treatments to target these areas prior to initiating PT.
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Figure 1. 
Forest plots showing differences in ABC-irritability scores between PT and PEP by 
moderator variables at the week 24 endpoint. P-values are from 3-way interactions of 
treatment by time by moderator
ECI early childhood inventory, ES effect size, ABC aberrant behavior checklist, PDD 
pervasive developmental disorder, CYBOCS-PDD Children’s Yale-Brown Obsessive 
Compulsive Scale, ADOS Autism Diagnostic Observational Schedule, ADHD attention 
deficit hyperactivity disorder. For continuous variables, the red circle corresponds to the top 
quartile, while the blue squares correspond to the lowest three quartiles. In general, greater 
separation of the circle and the square suggest different responses for children scoring high 
and low, respectively, on the potential moderator. As the circle and square become closer 
together, the likelihood that the variable is a moderator declines. Effect size estimated by the 
difference in the least squares means at week 24 divided by the pooled standard deviation at 
baseline for the entire study sample.
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Figure 2. 
Forest plots showing differences in HSQ scores between PT and PEP by moderator variables 
at the week 24 endpoint. P-values are from 3-way interactions of treatment by time by 
moderator
ECI early childhood inventory, ES effect size, ABC aberrant behavior checklist, PDD 
pervasive developmental disorder, CYBOCS-PDD Children’s Yale-Brown Obsessive 
Compulsive Scale, ADOS Autism Diagnostic Observational Schedule, ADHD attention 
deficit hyperactivity disorder For continuous variables, the red circle corresponds to the top 
quartile, while the blue squares correspond to the lowest three quartiles. In general, greater 
separation of the circle and the square suggest different responses for children scoring high 
and low, respectively, on the potential moderator. As the circle and square become closer 
together, the likelihood that the variable is a moderator declines. Effect size estimated by the 
difference in the least squares means at week 24 divided by the pooled standard deviation at 
baseline for the entire study sample.
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Figure 3. 
Forest plots comparing the likelihood of treatment response on CGI-I between PT and PEP 
by moderator variables at the week 24 endpoint. P-values are from 3-way interactions of 
treatment by time by moderator.
ECI early childhood inventory, ES effect size, ABC aberrant behavior checklist, PDD 
pervasive developmental disorder, CYBOCS-PDD Children’s Yale-Brown Obsessive 
Compulsive Scale, ADOS Autism Diagnostic Observational Schedule, ADHD attention 
deficit hyperactivity disorder. For continuous variables, the red circle corresponds to the top 
quartile, while the blue squares correspond to the lowest three quartiles. In general, greater 
separation of the circle and the square suggest different responses for children scoring high 
and low, respectively, on the potential moderator. As the circle and square become closer 
together, the likelihood that the variable is a moderator declines.
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